Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
J J CornelissenA W Dekker

Abstract

To evaluate the mortality and morbidity associated with early discontinuation of intravenously administered antibiotics, we prospectively examined the incidence and cause of recurrent fever in patients with persistent neutropenia who responded to a short course of intravenous antibiotic therapy. Preventive measures included the use of oral ciprofloxacin as prophylaxis for infection by gram-negative bacteria during the entire neutropenic episode. The rate of response to either initial or modified intravenous antibiotic therapy was 96% (149 of 156 episodes of fever). Eighty-five patients had an episode of persistent neutropenia (median duration, 7 days; range, 1-36 days) after they responded to treatment. Seven of these patients had recurrent fever, including 2 with bacteriologically documented infections, 4 with probable fungal pneumonia, and 1 with documented pneumonia due to Aspergillus fumigatus. Two patients with probable fungal pneumonia died, while the other infectious episodes resolved completely. These results do not support the continuation of intravenous antibiotic therapy for febrile patients with persistent neutropenia who have responded to the antibiotic regimen while receiving prophylaxis with oral ciprofloxacin.

Citations

Dec 12, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J L ShenepK S Slobod
Dec 6, 2011·Journal of Paediatrics and Child Health·Aditi Vedi, Richard Cohn
Dec 11, 2013·Haematologica·Inge C GyssensUNKNOWN ECIL-4, a joint venture of EBMT, EORTC, ICHS and ESGICH of ESCMID
Feb 19, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Walter T HughesLowell S Young
Dec 10, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J-B MicolB Gachot
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas LehrnbecherUNKNOWN International Pediatric Fever and Neutropenia Guideline Panel
May 2, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas LehrnbecherLillian Sung
Feb 20, 2018·Infectious Diseases·Florence PasquierJean-Baptiste Micol
Jan 29, 2019·Expert Review of Anti-infective Therapy·Martin Schmidt-HieberEnrico Schalk
Oct 10, 2013·The Cochrane Database of Systematic Reviews·Liat VidalLeonard Leibovici
Dec 5, 2020·Hematology·C LoganR Taplitz
Jan 26, 2021·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Trang D TrinhSarah B Doernberg
Mar 5, 2019·International Journal of Antimicrobial Agents·Zoé Van de WyngaertSerge Alfandari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.